Doxorubicin pathways: pharmacodynamics and adverse effects.
about
Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative StressTreatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systemsGetting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrierChemoresistance and targeted therapies in ovarian and endometrial cancersSulforaphane protects the heart from doxorubicin-induced toxicitySkeletal Muscle an Active Compartment in the Sequestering and Metabolism of Doxorubicin ChemotherapyAnthracycline Drugs on Modified Surface of Quercetin-Loaded Polymer Nanoparticles: A Dual Drug Delivery Model for Cancer TreatmentCommon variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.The minipig as a new model for the evaluation of doxorubicin-induced chronic toxicity.PharmGKB: the Pharmacogenomics Knowledge Base.Non-coding polymorphisms in nucleotide binding domain 1 in ABCC1 gene associate with transcript level and survival of patients with breast cancer.Doxorubicin, DNA torsion, and chromatin dynamics.High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening.Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization.Doxorubicin activates the Notch signaling pathway in osteosarcoma.Doxorubicin-conjugated β-NaYF4:Gd(3+)/Tb(3+) multifunctional, phosphor nanorods: a multi-modal, luminescent, magnetic probe for simultaneous optical and magnetic resonance imaging and an excellent pH-triggered anti-cancer drug delivery nanovehicle.Styrene maleic acid micelles as a nanocarrier system for oral anticancer drug delivery - dual uptake through enterocytes and M-cells.Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications.Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac ToxicityPharmGKB summary: very important pharmacogene information for G6PD.Functionalization of Carbon Nanomaterial Surface by Doxorubicin and Antibodies to Tumor Markers.Polyphenols act synergistically with doxorubicin and etoposide in leukaemia cell lines.The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patientsTanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way.Melissa officinalis Protects against Doxorubicin-Induced Cardiotoxicity in Rats and Potentiates Its Anticancer Activity on MCF-7 CellsLong-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.Cardanol isolated from Thai Apis mellifera propolis induces cell cycle arrest and apoptosis of BT-474 breast cancer cells via p21 upregulationPossible Protective Effect of Diacerein on Doxorubicin-Induced Nephrotoxicity in Rats.Doxorubicin induced heart failure: Phenotype and molecular mechanisms.Identifying anti-cancer drug response related genes using an integrative analysis of transcriptomic and genomic variations with cell line-based drug perturbationsCore-Shell Silver/Polymeric Nanoparticles-Based Combinatorial Therapy against Breast Cancer In-vitro.Gold Nanoantenna-Mediated Photothermal Drug Delivery from Thermosensitive Liposomes in Breast Cancer.Chemotherapeutic drug-specific alteration of microvascular blood flow in murine breast cancer as measured by diffuse correlation spectroscopy.Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.pH-Responsive Triblock Copolymeric Micelles Decorated with a Cell-Penetrating Peptide Provide Efficient Doxorubicin DeliveryTargeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model.Rapid emergence and mechanisms of resistance by U87 glioblastoma cells to doxorubicin in an in vitro tumor microfluidic ecology.Multidrug-resistant breast cancer: current perspectives.A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC.
P2860
Q26780547-D34CA409-E40B-40D4-9EAD-B501272D528AQ27025606-56CA90F0-59C0-47CB-96B3-031EC821DEACQ28071873-1ACA4F6B-86C5-44A5-97BD-667F57C1B263Q28073246-3FB3BEB7-7EA3-427F-B27A-7E4FD14F0A29Q28387218-87857623-1023-404E-893B-74309387DD2DQ28548399-3A24C3C6-D71A-4472-8C21-F1228754E09AQ28552231-D772ABB4-3F06-49BD-AE50-731912B413F8Q30418239-AF071968-7BC0-4A7F-820D-0895D805D62CQ33427938-5D91F61E-B026-42FF-BF32-CB9B8C52D9E1Q33855594-D67C3879-AD79-420A-8A2E-21BAC5C7E992Q33982601-CF84C537-643E-438B-A3FB-493F69A78368Q34039414-B6C8EEFD-DD8E-4621-83FF-A1E55D3303CDQ34044936-DD7255FC-025F-4B2E-B70F-45DF08722131Q34101055-21DA47BF-BD24-4059-AB62-641C144937B0Q34400600-D463D8B2-9B26-47B9-8499-1B4D175D754FQ35759038-35E847CC-4523-4EF4-98A4-B9DD557743E8Q35832958-F21F22C9-86CD-4AC4-BB3C-95D09D312716Q35892628-4C527112-C622-4A3C-AB7C-735F57F63DA2Q35989515-5A480B13-EF2C-4C04-836A-A7EF61F4A92FQ35999766-B0718A18-0FEE-4EA1-8665-7B07253F9550Q36055205-5E8E711E-18CF-47AF-B536-A94284CC07EAQ36064150-C74D0DDC-94DC-4023-9C82-11FF9A3E2E61Q36110039-AB716141-E226-4CC9-BD09-28AC1D18C429Q36154045-662D1201-1DCA-4E07-8859-C7112725AF37Q36198145-0BDF4535-4582-4579-A015-5BA88432289FQ36202577-3DBC3366-C40F-4A61-AF60-63F34B27984EQ36316604-418F035C-C533-4342-A23E-F31594121264Q36393277-11D41136-5A6A-4EC6-9E8B-18B87585B1DEQ36556327-9A65582F-43BE-41E0-8568-E647F246D6A4Q36912561-B56D895A-4E94-4878-91C7-B709CFFEAA8BQ36962620-857B5015-DC0A-4542-8571-16BDB411CA99Q37153729-70A9CC82-5D69-4104-9F12-464E9348550FQ37262447-25018C65-F8D9-444B-95BE-9A27E67BD6CBQ37270175-8EC97F5C-2240-426C-B075-7E6089B8BBA8Q37378179-8588A21B-775A-4495-8F00-F2EFDB933D31Q37474912-CAEB1450-D6BF-483C-B042-92ECED11F970Q37476433-C94DD40F-2E30-49E3-87DD-FE29AC591A14Q37514977-691CD940-3ED6-47B7-86D1-C966C86592C0Q37593383-B928892C-B8BF-43E0-A82D-4CA42C79C55AQ37603481-A4DF9077-BBDA-433E-8243-EFCD9742FD7C
P2860
Doxorubicin pathways: pharmacodynamics and adverse effects.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Doxorubicin pathways: pharmacodynamics and adverse effects.
@en
type
label
Doxorubicin pathways: pharmacodynamics and adverse effects.
@en
prefLabel
Doxorubicin pathways: pharmacodynamics and adverse effects.
@en
P2093
P2860
P1476
Doxorubicin pathways: pharmacodynamics and adverse effects.
@en
P2093
Caroline F Thorn
Connie Oshiro
Howard McLeod
Sharon Marsh
Teri E Klein
Tina Hernandez-Boussard
P2860
P304
P356
10.1097/FPC.0B013E32833FFB56
P50
P577
2011-07-01T00:00:00Z